Efficacy and Safety of Bempedoic Acid in Japanese Patients With Hypercholesterolemia - A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (the CLEAR-J Trial).
Yamashita S, Kiyosue A, Fujita H, Yokota D, Nakamura Y, Yasuda S.
Circ J. 2025 Jul 25;89(8):1256-1265. doi: 10.1253/circj.CJ-25-0089. Epub 2025 Apr 28.
Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia.
Wang X, Qiu M, Cheng Z, Ji X, Chen J, Zhu H, Tang Y, Huang Z, Su G, Wang G, Huang Z, Yao Z, Lin J, Sun Y, Li S, Shao C, Zhao Y, Bai X, Han Y.
J Am Heart Assoc. 2024 Jun 4;13(11):e033669. doi: 10.1161/JAHA.123.033669. Epub 2024 May 31.
Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab.
Zhang Y, Pei Z, Chen B, Qu Y, Dong X, Yu B, Wang G, Xu F, Lu D, He Z, Chen B, Ma L, Wang M, Li B, Xia M, Zheng B, Huo Y.
Pharmacol Res. 2024 Sep;207:107340. doi: 10.1016/j.phrs.2024.107340. Epub 2024 Aug 5.
Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15.
Yamashita S, Kiyosue A, Maheux P, Mena-Madrazo J, Lesogor A, Shao Q, Tamaki Y, Nakamura H, Akahori M, Kajinami K.
J Atheroscler Thromb. 2024 Jun 1;31(6):876-903. doi: 10.5551/jat.64454. Epub 2024 Jan 14.
Association of sex hormone-binding globulin and dyslipidemia with Japanese postmenopausal women: a cross-sectional study.
Ichikawa T, Okada H, Hamaguchi M, Hara M, Takashima N, Suzuki S, Tanoue S, Kato Y, Nagayoshi M, Tamura T, Fukui M, Matsuo K.
Lipids Health Dis. 2025 Jun 10;24(1):212. doi: 10.1186/s12944-025-02634-2.
Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials.
Qi L, Shen H, Chai M, Chen B, He Y, Shi X, Lian Q, Zhao W, Qu Y, Qian L, Zhang J, Li H, Zhou Y, Huo Y.
Cardiovasc Diabetol. 2025 Jul 3;24(1):264. doi: 10.1186/s12933-025-02816-3.
Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial.
Shao C, Zhang S, Cheng Z, Yang K, Wang G, Shi X, Yang H, Ji Y, Li H, Zhang S, Ma J, Pei Z, Zhang Y, Li Y, Li L, Zheng Y, Shao C, Zhang M, Hao Y, Tang YD.
Atherosclerosis. 2025 Aug;407:120408. doi: 10.1016/j.atherosclerosis.2025.120408. Epub 2025 Jun 16.
Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trial.
Ji X, Xia J, Zhang H, Ren C, Ma G, Fu S, Zhang J, Chen Y, Han X, Zhang J, Fang Z, Yang B, Yang B, Huang W, Yin G, Qi H, Gong H, Wang D, Hao L, Zhao X, Pei Z, Wang P, Li X, Lin L, Li D, Li Z, Zhang L, Yin B, Cheng Y, You Z, Sheng J, Wu J, Chen L, Fan Z, Zhao W, Zhao S.
Lipids Health Dis. 2025 Jul 22;24(1):249. doi: 10.1186/s12944-025-02670-y.
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial.
Lin J, Ji Y, Wang G, Ma X, Yao Z, Han X, Chen J, Chen J, Huang W, Xu G, Peng D, Yan P, Qiao P, He Y, Tang Y, Wang M, Zhang M, Yu J, Hao Y, Ma C.
Atherosclerosis. 2025 Apr;403:119120. doi: 10.1016/j.atherosclerosis.2025.119120. Epub 2025 Jan 29.
Familial hypercholesterolemia in Chinese children and adolescents: a multicenter study.
Huang MN, Wang CC, Ma MS, Chi MZ, Zhou Q, Jiang LH, Wang CL, Lu M, Chen XQ, Cheng YY, Ke Q, Wang DY, Qian XX, Ying XM, Zhang JP, Shen QH, Liu LF, Gu R, Zhang ZJ, Feng JH, Wang M, Zhu MQ, Huang K, Fu JF, Zou CC.
Lipids Health Dis. 2024 Dec 27;23(1):423. doi: 10.1186/s12944-024-02406-4.
